- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 study to look at RP-6306 in combination with FOLFIRI as a treatment for Advanced Solid Tumours
Doctors are testing a new treatment called RP-6306 with standard chemotherapy (FOLFIRI) for people with advanced cancers. This early-stage study checks if the combination is safe and helps patients. It's for adults, and you won't know which treatment you get.
Spain - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - authorisedHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF VVD-159642 AS A SINGLE AGENT AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
This study is testing a new medicine, VVD-159642, for people with advanced solid cancers. It's an early-stage trial looking at how safe the medicine is, what side effects it might have, and if it helps fight cancer. It will be given alone and with other treatments.
Spain - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
This study is testing a new drug (REGN10597) for cancers like melanoma and kidney cancer. It aims to see how safe it is, how well it's tolerated, and if it helps shrink tumours, either alone or with an existing treatment called Libtayo.
Italy · Spain · Germany - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
France · Spain